1 the sclera subjects to vigorous clearance by
episcleral and choroidal circulation; in addition, the p
2 The left eye had
episcleral and conjunctival injection, clear cornea, a d
3 P) was elevated by laser photocoagulation of
episcleral and limbal veins.
4 ace, measured 9 x 6 x 3 mm, and exhibited no
episcleral attachment or ocular involvement.
5 s a novel technique for quantifying absolute
episcleral blood flow in humans.
6 oma treated with iodine 125 or ruthenium 106
episcleral brachytherapy between January 1, 2004, and De
7 A total of 375 eyes treated with
episcleral brachytherapy for posterior uveal melanoma fr
8 Vision loss following
episcleral brachytherapy for uveal melanoma is difficult
9 melanoma from 1995 to 2016 and treated with
episcleral brachytherapy were included.
10 s developed to predict vision loss following
episcleral brachytherapy.
11 counseling for patients being evaluated for
episcleral brachytherapy.
12 ing brachytherapy are uncommon 5 years after
episcleral brachytherapy.
13 t were secured by suturing, to form a sealed
episcleral chamber that was filled with a fluorescein so
14 These results suggest that the
episcleral circulation is under tonic neural control and
15 The
episcleral cyclosporine implant shows promise in reducin
16 This preclinical evaluation showed that the
episcleral cyclosporine implant was safe, delivered pote
17 Episcleral cyclosporine implants were manufactured with
18 An
episcleral exoplant facilitates diffusion of fluorescein
19 dium fluorescein (fluorescein, 376 Da) or an
episcleral exoplant loaded with fluorescein.
20 More than 34% of the
episcleral hydrogel explants developed symptomatic swell
21 The ability of an
episcleral implant at the equator of the eye to deliver
22 assess the toxicity of a cyclosporine (CsA)
episcleral implant for the prevention of high-risk kerat
23 ysis of the ocular drug distribution from an
episcleral implant showed that the elimination rate cons
24 porine in the subconjunctival space with the
episcleral implant was an effective means of delivering
25 Episcleral implants are safe and effective at delivering
26 In vivo,
episcleral implants at the equator of the eye did not de
27 Episcleral implants in vivo delivered a mean total of 2.
28 CsA
episcleral implants were made with a high (implant A) or
29 patients with unilateral anterior scleral or
episcleral inflammation.
30 leading to optic nerve damage was induced by
episcleral injection of hypertonic saline, which caused
31 racterized by corneal haze, conjunctival and
episcleral injection, corneal infiltrates, and neovascul
32 en 1 and 3 months, at the CAG and underlying
episcleral levels, respectively.
33 The three-vein
episcleral/
limbal vein occlusion model for inducing glau
34 male Wistar rats (150-180 g) by cautery of 3
episcleral/
limbal veins.
35 t surgical removal of a symptomatic, swollen
episcleral MIRAgel (MIRA Inc., Waltham, MA) explant at t
36 with equine recurrent uveitis (ERU) received
episcleral or deep scleral lamellar CsA implants and wer
37 There was no case of
episcleral or orbital retinoblastoma extension or remote
38 ic Resonance Imaging revealed a left lateral
episcleral orbital mass and an incisional biopsy confirm
39 hotocoagulation may be considered only after
episcleral pigmentation has become less so as to avoid t
40 I(125) brachytherapy was administered via
episcleral plaque according to a standard protocol.
41 ye retention in patients treated with repeat
episcleral plaque brachytherapy (EPBT) for locally recur
42 Episcleral plaque brachytherapy (EPBT) provides effectiv
43 r high-risk UM (tumors deemed unsuitable for
episcleral plaque brachytherapy).
44 In cases where intratumor/
episcleral plaque edema or hemorrhage shifted the dose t
45 were 11 patients (47.8%) who received prior
episcleral plaque.
46 ; meibomian glands; skin; retina-choroid; or
episcleral regions.
47 mors were commonly dome shaped (75%) with an
episcleral sentinel vessel (75%).
48 t barriers to the movement of drugs from the
episcleral space into the vitreous in vivo.
49 Diffusion of CsA across the sclera from the
episcleral space was not a feasible method of drug deliv
50 depot of drug (100 microl) was added to the
episcleral surface while perfusing an irrigating solutio
51 vivo studies before subtenon TA injection or
episcleral TA-film implantation.
52 y conjunctivae bilaterally, having undergone
episcleral tattooing 7 weeks previously.
53 the few people in Britain to have undergone
episcleral tattooing for cosmetic purposes.
54 Episcleral tattooing is carried out by individuals with
55 ribing the first forays into the practice of
episcleral tattooing.
56 n exterior eye tissues including the cornea,
episcleral tissue, and sclera.
57 . 4%) or ciliary body (30% vs. 8%) lymphoma,
episcleral vascular congestion (40% vs. 16%), anterior c
58 hours) was a near complete blanching of the
episcleral vasculature, and a poorly defined wave was mi
59 o provide a more reliable approach to assess
episcleral vasculature.
60 by injection of hypertonic saline solution,
episcleral vein cauterization, or optic nerve transectio
61 Hypertonic saline was injected into a single
episcleral vein in 17 animals and awake IOP measured in
62 duced by hypertonic saline injection into an
episcleral vein in 20 adult male Brown-Norway rats.
63 cular pressure (IOP) was produced in rats by
episcleral vein injection of hypertonic saline (N = 30).
64 Episcleral vein injection of hypertonic saline is more l
65 own Norway rats (N = 16) received unilateral
episcleral vein injection of hypertonic saline to elevat
66 A single
episcleral vein injection of hypertonic saline was used
67 ateral IOP elevation was produced in rats by
episcleral vein injection of hypertonic saline.
68 monitor chronically elevated IOP produced by
episcleral vein injection of hypertonic saline.
69 own Norway rats were-administered unilateral
episcleral vein injections of hypertonic saline to produ
70 induced in the left eye by hypertonic saline
episcleral vein injections.
71 to optic nerve damage was induced using the
episcleral vein occlusion model.
72 elevated by injecting 1.9 M saline into the
episcleral vein, as previously described in Brown Norway
73 532 nm aimed at the trabecular meshwork and
episcleral veins (combination treatment group) or only a
74 mice by laser photocoagulation of limbal and
episcleral veins 270 degrees to 300 degrees circumferent
75 DTPA from the subconjunctival space into the
episcleral veins and conjunctival lymphatics was 3-log u
76 Diode laser treatment of ICG saturated
episcleral veins causes a chronic elevation of IOP and s
77 ser cauterization of trabecular meshwork and
episcleral veins in rat eyes.
78 Laser photocoagulation of limbal and
episcleral veins induces transient ocular hypertension i
79 sive eye in which cauterizing limbal derived
episcleral veins leads to increase in the intraocular pr
80 onal area (CSA) of the aqueous column within
episcleral veins was correlated with intraocular pressur
81 flow pathway, preventing flow to the visible
episcleral veins.
82 in rats by hypertonic saline injections into
episcleral veins.
83 d by injection of hypertonic saline into the
episcleral veins.
84 s with 2- to 3-microm tips used to cannulate
episcleral veins.
85 mice by laser photocoagulation of limbal and
episcleral veins.
86 e (12.5-14.5 mmHg) by cauterization of three
episcleral veins.
87 rapid, non-invasive delineation of abnormal
episcleral venous plexus secondary to dural CCF.
88 iotz tonography, IOP by pneumotonometry, and
episcleral venous pressure (EVP) by automated venomanome
89 Episcleral venous pressure (EVP) was measured by gradual
90 Measurements of IOP,
episcleral venous pressure (EVP), conventional outflow f
91 acute elevations in IOP, suggesting elevated
episcleral venous pressure (EVP).
92 of the variation in IOP is due to changes in
episcleral venous pressure (EVP).
93 etermined by multiple flow-rate infusion and
episcleral venous pressure (Pe) measured by manometry.
94 d be reconciled only if nocturnal changes in
episcleral venous pressure and/or uveoscleral flow occur
95 Current measurements of
episcleral venous pressure are either invasive or provid
96 mechanisms are exertion-related increase in
episcleral venous pressure or ocular compression from sl
97 stigate whether changes in outflow facility,
episcleral venous pressure, or uveoscleral flow at night
98 ique altered tonographic outflow facility or
episcleral venous pressure.
99 choroidal hemangioma, and signs of elevated
episcleral venous pressure.
100 cy, any iridocorneal angle malformation, and
episcleral vessel patency in normal eyes vs all other ey
101 After total outflow was measured, the
episcleral vessels were blocked with cyanoacrylate to el
102 IOP was produced in rats by cautery of three
episcleral vessels.
103 ry to anterior segment dysgenesis had patent
episcleral vessels.